This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Health Stocks in Motion

Shares of Sonus Pharmaceuticals (SNUS) were among the best-performing health-related stocks Tuesday, rising 12% after the company signed a licensing deal with Schering AG , which also agreed to acquire about 15% of Sonus.

The deal gives Schering an exclusive license to Sonus' Tocosol paclitaxel anti-cancer product. As part of the deal, Schering will pay Sonus an upfront fee of $20 million and milestone payments of up to $132 million. "The collaboration with Sonus Pharmaceuticals strategically complements our innovative and extensive internal pipeline of systemic and targeted cancer therapies and reinforces our strong commitment to oncology," Schering said in a statement.

As for the equity investment, Schering bought 3.9 million shares $4.02 apiece, resulting in proceeds of about $15.7 million. Schering also acquired five-year warrants to buy 975,000 shares at an exercise price of $4.42 a share. Shares of Sonus recently traded up 47 cents to $4.53.

Pharmaceutical Product Development (PPDI) rose 11% after the company posted third-quarter results that topped expectations. The drug developer earned $38.4 million, or 66 cents a share, on sales of $273.3 million. Excluding items, the company would have earned 70 cents a share. Analysts polled by Thomson First Call were expecting earnings of 66 cents a share on sales of $246.7 million. A year earlier, the company earned $25 million, or 44 cents a share, on sales of $215.8 million. Shares were trading up $6.21 to $62.46.

Shares of AngioDynamics (ANGO) rose 10% after the company signed a distribution agreement with Bioniche Pharma Group and lifted its 2006 earnings and sales guidance ahead of analysts' expectations. The distribution agreement allows AngioDynamics to exclusively market and distribute Bioniche's Sotradecol injection to radiologists and surgeons in the U.S. Sotradecol, which treats varicose veins, is the only FDA-approved sodium tetradecyl sulfate injection in the U.S.

AngioDynamics now expects 2006 earnings, excluding items, of $7.1 million on sales of at least $76 million. Previously, the company said that it would earn $6.1 million on sales of at least $72 million. Analysts had been expecting earnings of $6.4 million, or 50 cents a share, on sales of $73.9 million. Shares were trading up $1.88 to $21.59.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,122.01 +15.31 0.09%
S&P 500 2,000.12 +0.10 0.00%
NASDAQ 4,569.6210 -1.0160 -0.02%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs